Compound Evaluation Program
Clinical Trial Philosophy in Pre-clinical Studies
Invivotek offers a customized battery of in vivo bioassays and disease models to:
(i) Assess the therapeutic efficacy of lead compounds and/or drug development candidates by analyzing their effects on key physiological functions in animals;
(ii) Generate data and reagents for evaluation mechanism of action of test agents and efficacy biomarker discovery
(iii) Screen for potential side effects caused by the administration of such compounds at relevant doses;
View EnlargeOur multidisciplinary team of biomedical experts works collaboratively under one roof to assess the effect of the test agents in the context of whole animal. We have extensive experience performing efficacy studies for small molecule compounds, biologics, stem cell therapeutics, and nanoparticles via various routes of administration.
The research needs of our clients for in vivo characterization of potential therapeutic agents vary depending on the stage and specific goals of a drug discovery and development program. Our scientific experts work with every client to custom-design each study to best meet our clients’ needs and to provide interpretive data analysis at the end of each study. Our collective expertise related to multiple therapeutic areas and the wealth of pharmacologically validated in vivo assays allow us to assess the effects of the compound related to various physiological systems. The Invivotek Compound Evaluation Program includes a variety of disease models and non-disease-model in vivo bioassays related to the following therapeutic areas:
Inflammation and Allergy
Our in vivo testing capabilities are supplemented by biochemical and molecular biology techniques. In addition, we offer functional assays using primary cell cultures established from various mouse tissues under disease model and normal conditions. These assays provide tools to study mechanism of action of various test therapeutics or potential target genes and to explore drug efficacy biomarkers.
Our non-invasive biophotonic imaging capabilities support studies to evaluate biodistribution of bioluminescently and/or fluorescently labeled test agents in healthy animals and in disease models.